BCR and prostate carcinoma: Fraser et al.34 study in-depth the class of localized, non-indolent prostate cancer and propose a multi-modal pool of biomarkers to predict disease relapse as indicated by BCR (this signature includes clinical, gene expression, methylation sites, SNV, and CNA).